These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 16886638)
1. Phase I/II study of paclitaxel + carboplatin for refractory or recurrent non-small cell lung cancer. Gemma A; Seike M; Kosaihira S; Minegishi Y; Noro R; Nara M; Hosomi Y; Okano T; Kokubo Y; Yoshimura A; Shibuya M; Kudoh S Anticancer Res; 2006; 26(4B):3083-7. PubMed ID: 16886638 [TBL] [Abstract][Full Text] [Related]
2. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646 [TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655 [TBL] [Abstract][Full Text] [Related]
5. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422 [TBL] [Abstract][Full Text] [Related]
6. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer]. Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022 [TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer. Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. Yoh K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Saijo N; Nishiwaki Y Lung Cancer; 2007 Oct; 58(1):73-9. PubMed ID: 17548127 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR; J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. Huber RM; Flentje M; Schmidt M; Pöllinger B; Gosse H; Willner J; Ulm K; J Clin Oncol; 2006 Sep; 24(27):4397-404. PubMed ID: 16983107 [TBL] [Abstract][Full Text] [Related]
13. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer]. Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Nakadate M; Yamazaki K; Konishi J; Kinoshita I; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M Anticancer Res; 2006; 26(5B):3767-72. PubMed ID: 17094399 [TBL] [Abstract][Full Text] [Related]
16. Weekly chemotherapy with cisplatin and paclitaxel in inoperable non-small cell lung cancer: an extended phase II study. Ferrigno D; Buccheri G Anticancer Res; 2005; 25(6C):4685-92. PubMed ID: 16334161 [TBL] [Abstract][Full Text] [Related]
17. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153 [TBL] [Abstract][Full Text] [Related]
18. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553 [TBL] [Abstract][Full Text] [Related]
19. [Phase I study of biweekly paclitaxel and carboplatin administration in patients with advanced non-small cell lung cancer]. Ichiki M; Rikimaru T; Gohara R; Oshita Y; Kamimura T; Hoashi S; Koga T; Aizawa H Gan To Kagaku Ryoho; 2002 Aug; 29(8):1389-94. PubMed ID: 12214466 [TBL] [Abstract][Full Text] [Related]
20. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]